{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T14:42:50Z","timestamp":1772462570247,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T00:00:00Z","timestamp":1537488000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.msard.2018.09.017","type":"journal-article","created":{"date-parts":[[2018,9,15]],"date-time":"2018-09-15T21:54:22Z","timestamp":1537048462000},"page":"211-218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice"],"prefix":"10.1016","volume":"26","author":[{"given":"Patricia K.","family":"Coyle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1843-5585","authenticated-orcid":false,"given":"Bhupendra","family":"Khatri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith R.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 E.","family":"Meca-Lallana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Cavalier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Rufi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myriam","family":"Benamor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthinathan","family":"Thangavelu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miqun","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Gold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1-2","key":"10.1016\/j.msard.2018.09.017_bib0001","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jns.2005.05.019","article-title":"Cognitive changes in early MS: a call for a common framework","volume":"245","author":"Achiron","year":"2006","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2018.09.017_bib0002","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health Qual. Life Outcomes"},{"issue":"1","key":"10.1016\/j.msard.2018.09.017_bib0003","doi-asserted-by":"crossref","first-page":"34","DOI":"10.7224\/1537-2073-12.1.34","article-title":"Assessing quality of life in patients with multiple sclerosis","volume":"12","author":"Bandari","year":"2010","journal-title":"Int. J. MS Care"},{"key":"10.1016\/j.msard.2018.09.017_bib0004","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/PPA.S24752","article-title":"A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence","volume":"6","author":"Barbosa","year":"2012","journal-title":"Patient Prefer. Adherence"},{"issue":"6","key":"10.1016\/j.msard.2018.09.017_bib0005","doi-asserted-by":"crossref","first-page":"284","DOI":"10.7224\/1537-2073.2014-057","article-title":"Factors associated with employment status in individuals with multiple sclerosis","volume":"17","author":"Cadden","year":"2015","journal-title":"Int. J. MS Care"},{"issue":"6","key":"10.1016\/j.msard.2018.09.017_bib0006","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.msard.2015.09.004","article-title":"Patient-reported outcomes in multiple sclerosis: relationships among existing scales and the development of a brief measure","volume":"4","author":"Chua","year":"2015","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2018.09.017_bib0010a","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1001\/jamaneurol.2013.6240","article-title":"Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study","volume":"71","author":"Cohen","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2018.09.017_bib0007","series-title":"Statistical Power Analysis for the Behavioral Sciences","first-page":"273","author":"Cohen","year":"1988"},{"key":"10.1016\/j.msard.2018.09.017_bib0008","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.msard.2015.11.006","article-title":"Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions","volume":"5","author":"Comi","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"9","key":"10.1016\/j.msard.2018.09.017_bib0009","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1177\/1352458512436594","article-title":"Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years","volume":"18","author":"Confavreux","year":"2012","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2018.09.017_bib0010","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","article-title":"Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Confavreux","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2018.09.017_bib0011","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.msard.2017.07.006","article-title":"Patient-reported outcomes in relapsing forms of MS: Real-world, global treatment experience with teriflunomide from the Teri-PRO study","volume":"17","author":"Coyle","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2018.09.017_bib0012","unstructured":"European Multiple Sclerosis Platform, 2015, MS Barometer 2015. [Available from: http:\/\/www.emsp.org\/projects\/ms-barometer\/]."},{"key":"10.1016\/j.msard.2018.09.017_bib0013","series-title":"Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC)","article-title":"Poster DX 48. Final outcomes from the teriflunomide TOWER extension study: up to 6 years of follow-up (core plus extension) in patients with relapsing forms of MS","author":"Freedman","year":"2016"},{"key":"10.1016\/j.msard.2018.09.017_bib0014","series-title":"AUBAGIO Prescribing Information","year":"2016"},{"issue":"4","key":"10.1016\/j.msard.2018.09.017_bib0015","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1177\/1756285616634247","article-title":"Therapy satisfaction and adherence in patients with relapsing-remitting multiple sclerosis: the THEPA-MS survey","volume":"9","author":"Haase","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"4","key":"10.1016\/j.msard.2018.09.017_bib0016","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1177\/1756285616634247","article-title":"Therapy satisfaction and adherence in patients with relapsing\u2013remitting multiple sclerosis: the THEPA-MS survey","volume":"9","author":"Haase","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"7","key":"10.1016\/j.msard.2018.09.017_bib0010c","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/jamaneurol.2016.0826","article-title":"Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment","volume":"73","author":"Hatcher","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2018.09.017_bib0017","series-title":"An evaluation using Teri-PRO study data","article-title":"Measuring treatment satisfaction in patients with RMS in the real world: is the TSQM fit for purpose?","author":"Hobart","year":"2016"},{"issue":"2","key":"10.1016\/j.msard.2018.09.017_bib0018","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1212\/WNL.45.2.251","article-title":"Disease steps in multiple sclerosis: a simple approach to evaluate disease progression","volume":"45","author":"Hohol","year":"1995","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2018.09.017_bib0019","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1177\/135245859900500508","article-title":"Disease steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression","volume":"5","author":"Hohol","year":"1999","journal-title":"Mult. Scler."},{"issue":"8","key":"10.1016\/j.msard.2018.09.017_bib0010b","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s00415-016-8177-1","article-title":"Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients","volume":"263","author":"Iaffaldano","year":"2016","journal-title":"J Neurol."},{"key":"10.1016\/j.msard.2018.09.017_bib0020","unstructured":"International Conference on Harmonisation Expert Working Group, 2016. ICH harmonised tripartite guideline\u2014guideline for good clinical practice E6(R1). [Available from: http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6\/E6_R1_Guideline.pdf]."},{"issue":"11","key":"10.1016\/j.msard.2018.09.017_bib0021","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.msard.2018.09.017_bib0022","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1177\/1352458507078388","article-title":"Validity of performance scales for disability assessment in multiple sclerosis","volume":"13","author":"Marrie","year":"2007","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.msard.2018.09.017_bib0023","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1177\/1352458516657440","article-title":"Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study","volume":"23","author":"McKay","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2018.09.017_bib0024","series-title":"Poster P43. Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase III trial (TEMSO)","author":"Miller","year":"2011"},{"issue":"10","key":"10.1016\/j.msard.2018.09.017_bib0025","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1474-4422(14)70191-7","article-title":"Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Miller","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2018.09.017_bib0026","unstructured":"Multiple Sclerosis International Federation. Atlas of MS 2013: mapping multiple sclerosis around the world. 2013."},{"issue":"10","key":"10.1016\/j.msard.2018.09.017_bib0027","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1212\/WNL.0000000000002441","article-title":"Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study","volume":"86","author":"O'Connor","year":"2016","journal-title":"Neurology"},{"issue":"14","key":"10.1016\/j.msard.2018.09.017_bib0028","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O'Connor","year":"2011","journal-title":"New Engl. J. Med."},{"issue":"6","key":"10.1016\/j.msard.2018.09.017_bib0029","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1212\/01.wnl.0000203121.04509.31","article-title":"A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses","volume":"66","author":"O'Connor","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.09.017_bib0030","series-title":"31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)","article-title":"Oral Presentation 229. Teriflunomide slows brain volume loss in relapsing MS: a SIENA analysis of the TEMSO MRI dataset","author":"Radue","year":"2015"},{"issue":"7","key":"10.1016\/j.msard.2018.09.017_bib0031","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002346","article-title":"Patient-reported outcomes and survival in multiple sclerosis: A 10-year retrospective cohort study using the Multiple Sclerosis Impact Scale-29","volume":"14","author":"Raffel","year":"2017","journal-title":"PLoS Med."},{"key":"10.1016\/j.msard.2018.09.017_bib0032","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2147\/PPA.S49903","article-title":"Patient perspectives on switching disease-modifying therapies in the NARCOMS registry","volume":"8","author":"Salter","year":"2014","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.msard.2018.09.017_bib0033","series-title":"AUBAGIO Summary of Product Characteristics","year":"2016"},{"issue":"12","key":"10.1016\/j.msard.2018.09.017_bib0034","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1212\/WNL.57.12.2236","article-title":"Influence of leisure activity on the incidence of Alzheimer's disease","volume":"57","author":"Scarmeas","year":"2001","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2018.09.017_bib0035","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1212\/WNL.52.1.63","article-title":"Reliability and validity of two self-report measures of impairment and disability for MS. North American Research Consortium on Multiple Sclerosis Outcomes Study Group","volume":"52","author":"Schwartz","year":"1999","journal-title":"Neurology"},{"issue":"S3","key":"10.1016\/j.msard.2018.09.017_bib0036","first-page":"85","article-title":"Evaluation of the long-term treatment effect of teriflunomide on cognitive outcomes and association with brain volume change: data from TEMSO and its extension study","volume":"23","author":"Sprenger","year":"2017","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2018.09.017_bib0037","unstructured":"Trust, M.S, 2016. Prevalence and incidence of multiple sclerosis. [Available from: https:\/\/www.mstrust.org.uk\/a-z\/prevalence-and-incidence-multiple-sclerosis]."},{"issue":"2","key":"10.1016\/j.msard.2018.09.017_bib0038","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10072-015-2400-1","article-title":"Relationship between brain volume loss and cognitive outcomes among patients with multiple sclerosis: a systematic literature review","volume":"37","author":"Vollmer","year":"2016","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2018.09.017_bib0039","series-title":"European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) - Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)","article-title":"The prevalence of multiple sclerosis in the united states: a population-based healthcare database approach","author":"Wallin","year":"2017"},{"issue":"10","key":"10.1016\/j.msard.2018.09.017_bib0040","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1177\/1352458513475723","article-title":"Magnetic resonance imaging outcomes from a phase III trial of teriflunomide","volume":"19","author":"Wolinsky","year":"2013","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2018.09.017_bib0041","unstructured":"World Medical Association, 2016. Declaration of Helsinki. Ethical principles for medical research involving human subjects [Available from: https:\/\/www.wma.net\/wp-content\/uploads\/2016\/11\/DoH-Oct2008.pdf]."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818303298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818303298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:43:54Z","timestamp":1761900234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034818303298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":44,"alternative-id":["S2211034818303298"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2018.09.017","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2018.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}